Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma

Table 3

Comparison of tumor-related factors between NBNC-HCCs and B/C-HCCs in each surveillance status.

Variable	Semiannual surveillance		value; (I) versus (II)	Without semiannual surveillance		value; (III) versus (IV)	value; (I) versus (III)
	(I) NBNC	(II) B/C		(III) NBNC	(IV) B/C
	DCP (mAU/mL)
≥40	6	18	0.04	13	25	0.02	0.22
≤39	6	63		5	35
AFP (ng/mL)
≥20.1	3	33	0.30	8	30	0.68	0.28
≤20.0	9	48		10	30
AFP-L3 (%)
≥10.0	1	14	0.43	5	14	0.70	0.19
≤9.9	11	67		13	46
Tumor size (mm)
≥21	3	16	0.67	16	39	0.051	<0.01
≤20.0	9	65		2	21
Tumor number )
1	8	53	0.93	8	32	0.51	0.23
≥2	4	28		10	28
Vascular invasion
Yes	0	2	0.58	6	4	<0.01	0.02
No	12	79		12	56
HCC stage (TNM)
III, IV	1	12	0.55	11	22	0.07	<0.01
I, II	11	69		7	38
Curative therapy
No	2	27	0.25	9	35	0.53	0.04
Yes	10	54		9	25

Curative therapy includes operative resection and radiofrequency ablation.
Comparison of NBNC-HCCs with versus without semiannual surveillance.